Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Castleark Management LLC

Castleark Management LLC lessened its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,010 shares of the biopharmaceutical company’s stock after selling 1,870 shares during the period. Castleark Management LLC’s holdings in Intra-Cellular Therapies were worth $4,177,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ITCI. Accredited Wealth Management LLC purchased a new stake in Intra-Cellular Therapies in the fourth quarter valued at about $28,000. Venturi Wealth Management LLC purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $96,000. Wilmington Savings Fund Society FSB increased its holdings in shares of Intra-Cellular Therapies by 55.7% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 2,069 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 740 shares in the last quarter. Covestor Ltd raised its position in shares of Intra-Cellular Therapies by 15.9% in the 4th quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 288 shares during the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new stake in Intra-Cellular Therapies in the 4th quarter worth approximately $184,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $131.87 on Thursday. Intra-Cellular Therapies, Inc. has a 52-week low of $64.72 and a 52-week high of $131.98. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The business has a 50-day simple moving average of $131.82 and a 200-day simple moving average of $114.77.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on ITCI. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Cantor Fitzgerald reissued a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Finally, Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Eleven research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $109.70.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.